{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T22:22:33Z","timestamp":1793485353330,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T00:00:00Z","timestamp":1750636800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.tjpad.2025.100261","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:51:15Z","timestamp":1751428275000},"page":"100261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Alzheimer\u2019s Disease Cooperative Study \u2013 Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity"],"prefix":"10.1016","volume":"12","author":[{"given":"Julie M.","family":"Chandler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire J.","family":"Lansdall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Belger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9608-3856","authenticated-orcid":false,"given":"Kaycee M.","family":"Sink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2875-9366","authenticated-orcid":false,"given":"Alexandra S.","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100261_bib0001","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jalz.2009.09.004","article-title":"Dependence as a unifying construct in defining Alzheimer's disease severity","volume":"6","author":"McLaughlin","year":"2010","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100261_bib0002","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13195-018-0414-7","article-title":"Utility of the Dependence Scale in dementia: validity, meaningfulness, and health economic considerations","volume":"10","author":"Zhu","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2025.100261_bib0003","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/gerona\/63.9.1005","article-title":"The relation of patient dependence to home health aide use in Alzheimer's disease","volume":"63","author":"Scherer","year":"2008","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.tjpad.2025.100261_bib0004","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s12603-009-0068-z","article-title":"Bridging from clinical endpoints to estimates of treatment value for external decision makers","volume":"13","author":"Zhu","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"10.1016\/j.tjpad.2025.100261_bib0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2014.03.001","article-title":"for the DADE Investigator Group. Dependence in Alzheimer's disease and service use costs, quality of life, and care partner burden: The DADE study","volume":"11","author":"Jones","year":"2015","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100261_bib0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2147\/CEOR.S81045","article-title":"Relationship between patient dependence and direct medical- social, indirect - and informal-care costs in Spain","volume":"7","author":"Darba","year":"2015","journal-title":"ClinicoEcon Outcomes Res"},{"issue":"4","key":"10.1016\/j.tjpad.2025.100261_bib0007","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer's disease facts and figures","volume":"18","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100261_bib0008","doi-asserted-by":"crossref","first-page":"M216","DOI":"10.1093\/geronj\/49.5.M216","article-title":"Assessing patient dependence in Alzheimer's disease","volume":"49","author":"Stern","year":"1994","journal-title":"J Gerontol"},{"key":"10.1016\/j.tjpad.2025.100261_bib0009","first-page":"115","article-title":"Clinical and economic characteristics of milestones along the continuum of Alzheimer's disease: Transforming functional scores into levels of dependence","volume":"2","author":"Kahle-Wrobleski","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"issue":"Suppl 2","key":"10.1016\/j.tjpad.2025.100261_bib0010","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100261_bib0011","first-page":"72","article-title":"Dependence levels as interim clinical milestones along the continuum of Alzheimer's disease: 18-Month results from the GERAS observational study","volume":"4","author":"Kahle-Wrobleski","year":"2017","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100261_bib0012","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-122392","article-title":"The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries\u2013study design and baseline findings","volume":"36","author":"Wimo","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100261_bib0013","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Alzheimer's disease cooperative study steering committee; Solanezumab Study Group. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100261_bib0014","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer's disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100261_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","article-title":"Efficacy and safety of lanabecestat for treatment of early and mild Alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials","volume":"77","author":"Wessels","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100261_bib0016","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100261_bib0017","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"TRAILBLAZER-ALZ 2 Investigators. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100261_bib0018","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","article-title":"GRADUATE I and II Investigators and the Gantenerumab Study Group. Two phase 3 trials of gantenerumab in early Alzheimer's disease","volume":"389","author":"Bateman","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100261_bib0019","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","article-title":"Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials","volume":"79","author":"Ostrowitzki","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100261_bib0020","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Tauriel Investigators. Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: A randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.tjpad.2025.100261_bib0021","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","article-title":"Lauriet investigators. Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100261_bib0022","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State\": a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.tjpad.2025.100261_bib0023","first-page":"227","article-title":"A combined measure of cognition and function for clinical trials: The integrated Alzheimer's Disease Rating Scale (iADRS)","volume":"2","author":"Wessels","year":"2015","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100261_bib0024","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200127","article-title":"Meaningful clinical changes in Alzheimer disease measured with the iADRS and illustrated using the donanemab TRAILBLAZER-ALZ study findings","volume":"13","author":"Wessels","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.tjpad.2025.100261_bib0025","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: Additions to the Alzheimer's Disease Assessment Scale that broaden its scope","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100261_bib0026","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100261_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1021792","article-title":"Sum of boxes of the clinical dementia rating scale highly predicts conversion or reversion in predementia stages","volume":"14","author":"Tzeng","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"Suppl 2","key":"10.1016\/j.tjpad.2025.100261_bib0028","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"10.1016\/j.tjpad.2025.100261_bib0029","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/geront\/20.6.649","article-title":"Relatives of the impaired elderly: Correlates of feelings of burden","volume":"20","author":"Zarit","year":"1980","journal-title":"Gerontologist"},{"key":"10.1016\/j.tjpad.2025.100261_bib0030","series-title":"The memory and behavior problems checklist, in Families under stress: Caring for the patient with Alzheimer\u2019s disease and related disorders","author":"Zarit","year":"1985"},{"key":"10.1016\/j.tjpad.2025.100261_bib0031","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.tjpad.2025.100261_bib0032","first-page":"199","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"6","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.tjpad.2025.100261_bib0033","unstructured":"EuroQol Research Foundation. EQ-5D-5L User Guide. 2019. Available from https:\/\/euroquol.org\/publicagtions\/user-guides. Accessed on 10 November 2024."},{"key":"10.1016\/j.tjpad.2025.100261_bib0034","series-title":"The Health Economics of Dementia","first-page":"465","author":"Wimo","year":"1998"},{"key":"10.1016\/j.tjpad.2025.100261_bib0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two randomized phase 3 studies of aducanumab in early Alzheimer's disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100261_bib0036","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:38:32Z","timestamp":1762673912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2274580725002043"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100261","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Alzheimer\u2019s Disease Cooperative Study \u2013 Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100261"}}